Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Xenoport Inc (NASDAQ: XNPT) acted responsibly on behalf of investors’ profitability in the planned $467 million sale to Arbor Pharmaceuticals LLC.

On May 23, 2016, Xenoport Inc (NASDAQ: XNPT) and Arbor Pharmaceuticals LLC announced that they had entered into a merger agreement. Under the terms of the merger agreement, Arbor Pharmaceuticals will offer Xenoport shareholders $7.03 per share in cash for all outstanding shares.    

Based in Santa Clara, CA, and founded in 1999 Xenoport Inc is engaged in developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders

The investigation focuses on whether NASDAQ: XNPT investors received the highest price and whether the directors of Xenoport Inc acted in the best interest of Xenoport Inc company and its shareholders.   

If you purchased Xenoport Inc (NASDAQ: XNPT) prior to May 23, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185